What We Have Learned so far From Single Cell Sequencing in Acute Kidney Injury.

Front Physiol

Division of Nephrology and Clinical Immunology, RWTH Aachen University Hospital, Aachen, Germany.

Published: June 2022

AI Article Synopsis

  • - Acute kidney injury (AKI) is a serious health issue that leads to high rates of illness and death, with currently no specific treatments beyond supportive care.
  • - Single-cell technologies have advanced our understanding of the genetic activities within specific cell types of the kidney, which is crucial for grasping how AKI develops and progresses to chronic kidney disease.
  • - This review aims to summarize and discuss significant findings related to AKI, highlighting the insights gained from single-cell approaches in kidney research.

Article Abstract

Acute Kidney injury is a major clinical problem associated with increased morbidity and mortality. Despite, intensive research the clinical outcome remains poor and apart from supportive therapy no other specific therapy exists. Single cell technologies have enabled us to get deeper insights into the transcriptome of individual cells in complex tissues like the kidney. With respect to kidney injury, this would allow us to better define the unique role of individual cell populations in the pathophysiology of acute kidney injury and progression to chronic kidney disease. In this mini review, we would like to give an overview and discuss the current major findings in the field of acute kidney injury through Single-Cell technologies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217124PMC
http://dx.doi.org/10.3389/fphys.2022.933677DOI Listing

Publication Analysis

Top Keywords

kidney injury
20
acute kidney
16
single cell
8
kidney
7
injury
5
learned single
4
cell sequencing
4
acute
4
sequencing acute
4
injury acute
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!